IFNA1 and lobular neoplasia: Molecules that have been targeted in drug development research for LN include BAFF, B cell surface markers (e.g., CD20 and CD22), immune co-stimulatory molecules, cytokines (IL-6, IFN-γ, IFN-α) and the IFN-α/β receptor (IFNAR) (Anders et al. 2020).